Evaluating remission of type 2 diabetes using a metabolic intervention including fixed‐ratio insulin degludec and liraglutide: A randomized controlled trial
Primary result · Diabetes relapseResult — go to the resultHazard ratio 0.63 95% CI 0.45–0.88Authors' conclusion
An intensive remission-induction intervention including fixed-ratio insulin degludec/liraglutide reduced the risk of type 2 diabetes relapse within 1 year without sustained remission.
Study context
- Population
- Insulin-naïve adults within 5 years of T2D diagnosis; age 57 ± 10 years, diabetes duration 2.6 ± 1.5 years, BMI 33.5 ± 6.5 kg/m², HbA1c 53 ± 7 mmol/molrandomized and analysed
- Participants
- 159 adults
- Comparison
- 16-week remission intervention vs standard care
- Interventionn = 79
- Controln = 80reference
Methodological detailsmulticentre, open-label
- Multicentre
- Open-label
Primary result
Diabetes relapse · 1 year after stopping glucose-lowering drugs
Hazard ratio
0.63
95% CI 0.45–0.88
P = 0.007
Interventionvs Control
HR 0.63 (95% CI 0.45–0.88); P = 0.007
As reported in the abstract
Further findings
HbA1c · end of 16-week intervention · lower HbA1c with Intervention
P < 0.0001
Weight loss · end of 16-week intervention · more weight lost with Intervention
P = 0.02
| Outcome | Intervention | Control | RR for remission (95% CI) | P value | |
|---|---|---|---|---|---|
| Remission · 12 weeks after intervention period | 17.7% | 12.5% | 1.42 (0.67–3.00) | P = 0.36 | |
| Remission · 52 weeks after intervention period | 6.3% | 3.8% | 1.69 (0.42–6.82) | ||
| 0.10.31310RR for remission (log scale) |
Original publication
Evaluating remission of type 2 diabetes using a metabolic intervention including fixed‐ratio insulin degludec and liraglutide: A randomized controlled trial. Diabetes Obes Metab. Published 6 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →